# Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

> **NCT00003583** · PHASE2 · UNKNOWN · sponsor: **University of Florida** · enrollment: 20 (estimated)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Lung Cancer
- Radiation Toxicity

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** cisplatin
- **DRUG:** etoposide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003583
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003583, "Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*